FRM
SGMO

Fox Run Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Fox Run Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,956
Closed -$59K – 854
2022
Q3 		$59K Buy
+11,956
New +$61.4K 0.02% 573
2021
Q3 		– Sell
-12,271
Closed -$147K – 597
2021
Q2 		$147K Buy
+12,271
New +$139K 0.13% 304
2018
Q3 		– Sell
-12,486
Closed -$177K – 793
2018
Q2 		$177K Sell
12,486
-12,425
-50% -$206K 0.06% 590
2018
Q1 		$473K Sell
24,911
-38,164
-61% -$816K 0.11% 331
2017
Q4 		$1.03M Buy
63,075
+49,175
+354% +$732K 0.3% 63
2017
Q3 		$209K Sell
13,900
-400
-3% -$4.42K 0.06% 593
2017
Q2 		$126K Buy
+14,300
New +$91.7K 0.04% 589

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fox Run Management's SGMO Position: Q4 2022 in Review

Fox Run Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2022, closing a stake of 11,956 shares — an estimated $59K sold.

Fox Run Management first reported a position in SGMO in Q2 2017 and held it in 7 quarters. The position peaked at $1.03M in Q4 2017. 182 funds tracked by Wall St. Rank hold SGMO as of Q4 2022.

  • Fox Run Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2022 after selling out during the quarter.
  • Fox Run Management sold 11,956 SANGAMO THERAPEUTICS INC shares in Q4 2022, an estimated $59K.
  • Fox Run Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2017 and held it in 7 quarters.
  • Fox Run Management's SANGAMO THERAPEUTICS INC position peaked at $1.03M in Q4 2017.
  • 182 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2022.

Based on Fox Run Management's 13F filing for Q4 2022, filed 7 Feb 2023.